Matrix Service Company Sets Date for Release of Fiscal Year 2026 First Quarter Results and Conference Call

(NASDAQ:MTRX), TULSA, Okla., Oct. 21, 2025 (GLOBE NEWSWIRE) — Matrix Service Company (Nasdaq: MTRX), a leading provider of engineering and construction services to the energy and industrial markets, announced today that it will release first quarter Fiscal 2026 results after market on Wednesday, November 5, 2025. On Thursday, November 6, 2025, at 10:30 a.m. Eastern […]

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

(NASDAQ:MDGL), CONSHOHOCKEN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on October 15, 2025 to 19 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The

Remitly to Report Third Quarter Financial Results on November 5, 2025

(NASDAQ:RELY), SEATTLE, Oct. 21, 2025 (GLOBE NEWSWIRE) — Remitly Global, Inc. (NASDAQ: RELY) (“Remitly”), a trusted provider of digital financial services that transcend borders, today announced that it will report third quarter financial results after the market close on Wednesday, November 5, 2025. Management will host a conference call and live webcast to present the

InspireMD to Announce Third Quarter 2025 Financial Results

(NASDAQ:NSPR), MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard(R) Prime carotid stent system for the prevention of stroke, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, InspireMD will host a conference call and webcast

Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders

Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders GlobeNewswire October 21, 2025 WOODCLIFF LAKE, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the voting results for each of the matters presented at the Company's 2025 annual meeting of stockholders (the “Annual

Inotiv, Inc. to Participate in Three Investor Conferences in November 2025

Inotiv, Inc. to Participate in Three Investor Conferences in November 2025 GlobeNewswire October 21, 2025 WEST LAFAYETTE, Ind., Oct. 21, 2025 (GLOBE NEWSWIRE) — Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services,

Inspired to Report Third Quarter 2025 Results and Hold Conference Call on November 5

Inspired to Report Third Quarter 2025 Results and Hold Conference Call on November 5 GlobeNewswire October 21, 2025 NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) — Inspired Entertainment, Inc. (“Inspired” or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware and services, announced that it will report financial results for the

Hanmi Reports 2025 Third Quarter Results

Hanmi Reports 2025 Third Quarter Results GlobeNewswire October 21, 2025 LOS ANGELES, Oct. 21, 2025 (GLOBE NEWSWIRE) — Hanmi Financial Corporation (NASDAQ: HAFC or “Hanmi”), the parent company of Hanmi Bank (the “Bank”), today reported financial results for the third quarter of 2025. Net income for the third quarter of 2025 was $22.1 million, or

Bitfarms Announces Closing of US$500 Million of Convertible Senior Notes

Bitfarms Announces Closing of US$500 Million of Convertible Senior Notes GlobeNewswire October 21, 2025 Opportunistic capital raise for general corporate purposes Bitfarms used cash on hand to purchase capped calls to offset economic dilution up to a cap of 125% premium to the last reported sale price of Bitfarms' common shares on Nasdaq on the

Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update

Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update GlobeNewswire October 21, 2025 SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of

Scroll to Top